Diego A. Díaz García/X
May 29, 2025, 19:20
Diego A. Díaz García: sq-NSCLC Data Shows Benmelstobart Plus Chemo as Promising New 1L Option
Diego A. Díaz García, Medical Oncologist, CEO and Founder at CánCare, shared a post on X:
“TQB2450-III-12
Benmelstobart plus chemo – benmelstobart plus anlotinib vs Tislelizumab plus chemo in 1L sq-NSCLC shows:
Median PFS: 10.1 vs 7.8 mo (HR 0.64, p=0.0038)
ORR: 72% vs 65%
Benefit consistent across subgroups (PD-L1 1–49%, ECOG 0, age <65)
Manageable safety
Promising new 1L option.”
More posts featuring Diego A. Díaz García.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32